Delisting risk
Sunshine Biopharma
Commercializer of Canadian generic medicines with early-stage oncology and antiviral research.
$1.14
After-hours close0.00 (0.00%)
At close$1.14(−10.24%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 2.87%
Shares outstanding 2.38M · Float 498.2K · 21.0% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Mitchell P. Kopin | 9.99% | 13G | May 23, 2025 ↗ | |
| Alta Partners LLC | 8.60% | 200.0K | 13G | Jul 8, 2026 ↗ |
| L1 Capital Global Opportunities Master Fund, Ltd. | 5.83% | 13G | May 22, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| David Natan | director | 68.3K | 2.87% | Aug 11, 2026 |
1 ten-percent owner holds 0 shares by Form 4, outside the officers-and-directors figure above · 9 people have not refiled in the last 18 months (206 shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.